Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings

When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.